# FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients

> **NCT01864083** · EARLY_PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** Positron Emission Tomography (PET)
- **DRUG:** Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)
- **PROCEDURE:** Positron emission mammography (PEM) When available
- **PROCEDURE:** MR

## Key facts

- **NCT ID:** NCT01864083
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2017-08-29
- **Final completion:** 2017-08-29
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01864083

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01864083, "FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01864083. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*